1 (833) 242-CURE (2873) info@specicare.com

Brings with him a vision to continue leading-edge personalized treatment for cancer patients

GAINESVILLE, Ga.- SpeciCare recently announced the expansion of their mission to provide more personalized and effective treatment for cancer patients by bringing on Patrick deGrouchy as VP of Business and Market Development. The company, founded in 2015, will launch it’s first product, SpeciMatch to provide patients and providers an option to store live tumor tissue for cancer patients.

deGrouchy comes to SpeciCare with more than 30 years of experience in business and market development in the life sciences technology industry. For the last four years, he served as the Vice President for U.S. Operations and Business Development at StoreMyTumor, a global leader in viable cancerous tissue storage. At StoreMyTumor, he was responsible for setting the organization’s organic growth strategy; multiplying revenue and helping the company become a global leader in viable cancerous tissue storage.

“Pat deGrouchy brings unparalleled experience in this new field of precision medicine, where patient data and living patient tumor tissue are saved for research and then the information from this research is returned to the patient and his or her clinical care team,” said Ken Dixon, MD, FACS, founder of SpeciCare, and founder/surgical oncologist of Surgical Oncologists of Northeast Georgia. “His knowledge of the inner workings of this industry will be of central importance and help catapult our growth as a company. Most important, he shares our passion for extending a helping hand and hope to those with serious malignancies.” 

Prior to his previous role at StoreMyTumor, deGrouchy held several senior level positions in various life science companies that created new industry standards, including Nellcor in pulse oximetry and AG Mednet in the transfer of medical images via the internet. He also gained significant international experience as a Director in Siemens Medical’s international business development division. He has worked closely with eight of the top ten life science companies and their partners internationally to streamline and drive efficiencies in clinical trials.

“I have known Dr. Ken Dixon for years and have been impressed by his understanding that cancer care needs to become more personalized for the patient if we are to make significant inroads and the shared belief this starts with viable tumor storage,” deGrouchy said. “His passion to allow access to this cutting-edge precision medicine and personalized care for a significantly larger percentage of cancer patients is why I am very excited to join the SpeciCare organization. We need to create awareness in the cancer community of this potentially life changing option for patients, and I believe that under Ken’s direction we will quickly impact the future of cancer care.”

SpeciCare is a private company and has recently initiated the opportunity for accredited investors to be part of this innovative movement in precision medicine.  For interested accredited investors, please contact Dr. Dixon at 770-861-8747.